CL2019000542A1 - Compuestos de tetraciclina y métodos de uso de los mismos. - Google Patents
Compuestos de tetraciclina y métodos de uso de los mismos.Info
- Publication number
- CL2019000542A1 CL2019000542A1 CL2019000542A CL2019000542A CL2019000542A1 CL 2019000542 A1 CL2019000542 A1 CL 2019000542A1 CL 2019000542 A CL2019000542 A CL 2019000542A CL 2019000542 A CL2019000542 A CL 2019000542A CL 2019000542 A1 CL2019000542 A1 CL 2019000542A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- tetracycline compounds
- tetraciclines
- treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
- C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS PARA EL TRATAMIENTO DE CÁNCERES HEMATOLÓGICOS, TAL COMO LEUCEMIA MIELOIDE AGUDA, CON TETRACICLINAS, O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662381383P | 2016-08-30 | 2016-08-30 | |
US201662437533P | 2016-12-21 | 2016-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019000542A1 true CL2019000542A1 (es) | 2019-10-11 |
Family
ID=59982459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019000542A CL2019000542A1 (es) | 2016-08-30 | 2019-02-28 | Compuestos de tetraciclina y métodos de uso de los mismos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230031954A1 (es) |
EP (1) | EP3506908A1 (es) |
JP (1) | JP7184756B6 (es) |
KR (1) | KR102558540B1 (es) |
CN (1) | CN110167560B (es) |
AU (1) | AU2017319513B2 (es) |
BR (1) | BR112019003885A2 (es) |
CA (1) | CA3034891A1 (es) |
CL (1) | CL2019000542A1 (es) |
CO (1) | CO2019002975A2 (es) |
IL (1) | IL264878B (es) |
MA (1) | MA46102A (es) |
MX (1) | MX2019002453A (es) |
SG (2) | SG10202101986UA (es) |
WO (1) | WO2018045084A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2890673T (lt) | 2012-08-31 | 2019-04-10 | Tetraphase Pharmaceuticals, Inc. | Tetraciklino junginiai |
EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MX2018006207A (es) | 2015-11-19 | 2018-09-05 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
CN116514715A (zh) | 2015-12-22 | 2023-08-01 | 因赛特公司 | 作为免疫调节剂的杂环化合物 |
US20170320875A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2017281285C1 (en) | 2016-06-20 | 2022-05-12 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
KR102660864B1 (ko) | 2016-10-19 | 2024-04-25 | 테트라페이즈 파마슈티컬스, 인코포레이티드 | 에라바사이클린의 결정질 형태 |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
PT3774791T (pt) | 2018-03-30 | 2023-03-03 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
PE20211918A1 (es) | 2018-05-11 | 2021-09-28 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridin como inmunomoduladores de pd-l1 |
WO2021022258A1 (en) * | 2019-08-01 | 2021-02-04 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds for the treatment of hematological cancers |
TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
CR20220237A (es) | 2019-11-11 | 2022-08-05 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
CN116096714A (zh) | 2020-06-10 | 2023-05-09 | 安力高医药股份有限公司 | 用于治疗冠状病毒、小核糖核酸病毒和诺罗病毒感染的抗病毒化合物 |
KR20230117573A (ko) | 2020-11-06 | 2023-08-08 | 인사이트 코포레이션 | Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법 |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1077598A (en) * | 1965-05-12 | 1967-08-02 | Pfizer & Co C | Preparation of n-demethyl tetracyclines |
WO2005082860A1 (en) * | 2004-02-27 | 2005-09-09 | National Research Council Of Canada | Tetracyclines and their use as calpain inhibitors |
JP2007535565A (ja) * | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
RS54485B1 (en) * | 2008-08-08 | 2016-06-30 | Tetraphase Pharmaceuticals, Inc. | C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS |
US8367654B2 (en) | 2009-05-08 | 2013-02-05 | Tetraphase Pharmaceuticals, Inc. | 8-AZA tetracycline compounds |
ES2627772T3 (es) * | 2009-05-08 | 2017-07-31 | Tetraphase Pharmaceuticals, Inc. | Compuestos de tetraciclina |
NO2470500T3 (es) * | 2009-08-28 | 2018-03-03 | ||
EP2544692A4 (en) * | 2010-03-10 | 2013-08-07 | Univ Health Network | USE OF TIGECYCLINE FOR THE TREATMENT OF CANCER |
DK2552890T3 (en) * | 2010-03-31 | 2017-04-03 | Tetraphase Pharmaceuticals Inc | POLYCYCLIC TETRACYCLINE COMPOUNDS |
JP5996528B2 (ja) | 2010-05-21 | 2016-09-21 | アッヴィ・インコーポレイテッド | 5−ht受容体調節物質およびその使用方法 |
AR082633A1 (es) | 2010-08-12 | 2012-12-19 | Tetraphase Pharmaceuticals Inc | Analogos de tetraciclina |
SE536617C2 (sv) | 2012-06-28 | 2014-04-01 | Cargine Engineering Ab | Metod och positioneringssensorsammansättning för fastställning av en inbördes position mellan ett första objekt och ettandra objekt |
LT2890673T (lt) * | 2012-08-31 | 2019-04-10 | Tetraphase Pharmaceuticals, Inc. | Tetraciklino junginiai |
-
2017
- 2017-08-30 AU AU2017319513A patent/AU2017319513B2/en active Active
- 2017-08-30 EP EP17777422.1A patent/EP3506908A1/en active Pending
- 2017-08-30 WO PCT/US2017/049462 patent/WO2018045084A1/en unknown
- 2017-08-30 MA MA046102A patent/MA46102A/fr unknown
- 2017-08-30 MX MX2019002453A patent/MX2019002453A/es unknown
- 2017-08-30 CA CA3034891A patent/CA3034891A1/en active Pending
- 2017-08-30 IL IL264878A patent/IL264878B/en unknown
- 2017-08-30 US US16/328,559 patent/US20230031954A1/en active Pending
- 2017-08-30 JP JP2019511658A patent/JP7184756B6/ja active Active
- 2017-08-30 BR BR112019003885A patent/BR112019003885A2/pt unknown
- 2017-08-30 KR KR1020197008575A patent/KR102558540B1/ko active IP Right Grant
- 2017-08-30 SG SG10202101986UA patent/SG10202101986UA/en unknown
- 2017-08-30 SG SG11201901390TA patent/SG11201901390TA/en unknown
- 2017-08-30 CN CN201780064847.8A patent/CN110167560B/zh active Active
-
2019
- 2019-02-28 CL CL2019000542A patent/CL2019000542A1/es unknown
- 2019-03-27 CO CONC2019/0002975A patent/CO2019002975A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2019002453A (es) | 2020-02-17 |
CN110167560B (zh) | 2023-08-18 |
AU2017319513A1 (en) | 2019-04-04 |
MA46102A (fr) | 2019-07-10 |
IL264878B (en) | 2022-06-01 |
KR102558540B1 (ko) | 2023-07-21 |
CA3034891A1 (en) | 2018-03-08 |
KR20190042667A (ko) | 2019-04-24 |
BR112019003885A2 (pt) | 2019-05-28 |
CN110167560A (zh) | 2019-08-23 |
JP2019532031A (ja) | 2019-11-07 |
SG10202101986UA (en) | 2021-04-29 |
CO2019002975A2 (es) | 2019-06-19 |
EP3506908A1 (en) | 2019-07-10 |
JP7184756B2 (ja) | 2022-12-06 |
SG11201901390TA (en) | 2019-03-28 |
AU2017319513B2 (en) | 2022-05-19 |
WO2018045084A1 (en) | 2018-03-08 |
US20230031954A1 (en) | 2023-02-02 |
JP7184756B6 (ja) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000542A1 (es) | Compuestos de tetraciclina y métodos de uso de los mismos. | |
CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
CL2017003404A1 (es) | Compuestos antibacterianos | |
CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
CL2016002021A1 (es) | Ciclopropilaminas como inhibidores lsd1. | |
AR111346A1 (es) | Compuesto peptídico con acción activante sobre receptores gip | |
ECSP17042921A (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
CL2016001345A1 (es) | Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer. | |
CR20170573A (es) | Lactamas bicíclicas y métodos de uso de las mismas | |
CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
AR095039A1 (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
CR20150667S (es) | Portador, bandeja, abrazadera y perilla | |
GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
CL2017001511A1 (es) | Derivados de piperidina como inhibidores de hdac1/2. | |
CL2016001349A1 (es) | Uso de derivados de bencimidazol-prolina | |
CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
CL2016001368A1 (es) | Inhibidores de cinasa serina/treonina | |
CL2018000371A1 (es) | Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral. |